April 2012 Archives - Silence Therapeutics

News	Events
Publications	Companies
Clinical Trials

Biotechnology Business in The United States and Malaysia
0 Replies

April 30, 2012

Contine Reading & Discuss→

Posted in News | Tagged in | Report Linker Posted in Other News | Tagged in | Report Linker Posted in Reports | Tagged in | Report Linker Posted in Syndicated | Tagged in | Report Linker

Biotechnology Business in The United States and Malaysia
0 Replies

Contine Reading & Discuss→

Posted in News | Tagged in | Report Linker Posted in Other News | Tagged in | Report Linker Posted in Reports | Tagged in | Report Linker Posted in Syndicated | Tagged in | Report Linker

Cancer targets and uses thereof
0 Replies

Contine Reading & Discuss→

Posted in News Posted in Other News Posted in Patents Posted in Syndicated

Regulus Therapeutics Appoints Bruce Carter to its Board of Directors
0 Replies

LA JOLLA, Calif., April 30, 2012 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the appointment of Bruce Carter, Ph.D. to its Board of Directors. Dr. Carter currently serves as an independent member of the Board of Directors of... Contine Reading & Discuss→

Posted in Companies | Tagged in | Uncategorized Posted in News | Tagged in | Uncategorized Posted in Other News | Tagged in | Uncategorized Posted in Syndicated | Tagged in | Uncategorized

Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
0 Replies

April 26, 2012

Contine Reading & Discuss→

Posted in News Posted in Other News Posted in Patents Posted in Syndicated

Alnylam to Webcast Conference Call Discussing First Quarter 2012 Financial Results
0 Replies

CAMBRIDGE, Mass., Apr 26, 2012 (BUSINESS WIRE) --Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the first quarter ending March 31, 2012 on Thursday, May 3, 2012, after the U.S. financial markets close. Management will provide an update on... Contine Reading & Discuss→

Posted in Companies | Tagged in | Uncategorized Posted in News | Tagged in | Uncategorized Posted in Other News | Tagged in | Uncategorized Posted in Syndicated | Tagged in | Uncategorized

COMPOUND MOLECULE, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS THEREOF
0 Replies

April 25, 2012

Contine Reading & Discuss→

Posted in News Posted in Other News Posted in Patents Posted in Syndicated

NUCLEIC ACID MOLECULES INDUCING RNA INTERFERENCE, AND USES THEREOF
0 Replies

Contine Reading & Discuss→

Posted in News Posted in Other News Posted in Patents Posted in Syndicated

Use of a Histone Deacetylase Gene OsHDT1 in Enhancing Rice Heterosis
0 Replies

Contine Reading & Discuss→

Posted in News Posted in Other News Posted in Patents Posted in Syndicated

Henrik Stage Appointed Interim CEO of Santaris Pharma A/S
0 Replies

April 25th News Release: New CEO Hørsholm, Denmark, April 25th, 2012. — Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that Søren Tulstrup, President and Chief Executive Officer, has decided to leave the company per April 30, 2012, to pursue other opportunities. Henrik... Contine Reading & Discuss→

Posted in Companies | Tagged in | Santaris Posted in News | Tagged in | Santaris Posted in Other News | Tagged in | Santaris Posted in Syndicated | Tagged in | Santaris